Join to access to all OVN content. Join for Free

Results for 'post traumatic stress disorder'

...
OVN Avatar Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 8th • 5 mins read

...
Partner Avatar Tom Caravela
Mastering the First Impression

Jan 28th • 2 mins read

...
Partner Avatar Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons

May 16th • 2 mins read

...
Partner Avatar Tom Caravela
MSL Hiring and Recruitment: 5 Ways to Support Diversity and Inclusion

May 18th • 2 mins read

...
Partner Avatar Tom Caravela
Resume Writing and Editing Tips for Pharma Professionals

Aug 7th • 1 min read

...
Partner Avatar Tom Caravela
Combatting the “Summer Slow Down"​ – MSL Job Search Tips for Slower Months

Jun 22nd • 2 mins read

...
Partner Avatar Tom Caravela
7 High-Cost Interview Mistakes that are Easy to Avoid

Jul 27th • 1 min read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 20th • 10 mins read

...
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep
Accelerated drug approvals in oncology: Pros and cons

Sep 13th • 4 mins read

...
OVN Avatar Paulo J. Oliveira, Ana M. Urbano
“Oncometabolism: The switchboard of cancer: An editorial”

Jan 31st • 1 min read

...
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Nov 19th • 12 mins read

...
OVN Avatar Muneera Al Hussain
Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

Jun 23rd • 3 mins read

...
OVN Avatar Benjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman
Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study

Feb 16th • 7 mins read

...
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Jan 6th • 8 mins read

...
OVN Avatar S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar
New Realities of Phase I Clinical Trials in the Era of

Oct 6th • 5 mins read

...
OVN Avatar Natansh D. Modi, BPharm; Ahmad Y. Abuhelwa, PhD; Ross A. McKinnon, PhD
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

Jul 27th • 20 mins read

...
OVN Avatar Robbe Saesen, Georgios Kantidakis, Ann Marinus, Denis Lacombe, Isabelle Huys
How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer

Jul 31st • 45 mins read

...
Partner Avatar Envision Pharma Group
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 8th • 5 mins read

...
Partner Avatar Envision Pharma Group
Medical affairs: The power behind redefining commercialization

Aug 1st • 3 mins read

...
Partner Avatar Envision Pharma Group
Empowering people to drive medical affairs performance with AI

Aug 13th • 5 mins read

Related Topics

Loading...